{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:24:05Z","timestamp":1761895445252},"reference-count":50,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,5,7]],"date-time":"2012-05-07T00:00:00Z","timestamp":1336348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2012,7]]},"abstract":"Abstract<\/jats:title>Objectives<\/jats:title>The phase 3 VISTA<\/jats:styled-content> study (ClinicalTrials.gov<\/jats:ext-link> NCT<\/jats:styled-content>00111319) in transplant\u2010ineligible myeloma patients demonstrated superior efficacy with bortezomib\u2010melphalan\u2010prednisone (VMP<\/jats:styled-content>; nine 6\u2010wk cycles) vs. melphalan\u2010prednisone (MP<\/jats:styled-content>) but also increased toxicity. Health\u2010related quality of life (HRQ<\/jats:styled-content>oL; exploratory endpoint) was evaluated using the European Organization for Research and Treatment of Cancer (EORTC<\/jats:styled-content>) Quality of Life Questionnaire (QLQ<\/jats:styled-content>\u2010C30).<\/jats:p>The phase 3 VISTA<\/jats:styled-content> study (ClinicalTrials.gov<\/jats:ext-link> NCT<\/jats:styled-content>00111319) in transplant\u2010ineligible myeloma patients demonstrated superior efficacy with bortezomib\u2010melphalan\u2010prednisone (VMP<\/jats:styled-content>; nine 6\u2010wk cycles) vs. melphalan\u2010prednisone (MP<\/jats:styled-content>) but also increased toxicity. Health\u2010related quality of life (HRQ<\/jats:styled-content>oL; exploratory endpoint) was evaluated using the European Organization for Research and Treatment of Cancer (EORTC<\/jats:styled-content>) Quality of Life Questionnaire (QLQ<\/jats:styled-content>\u2010C30).<\/jats:p><\/jats:sec>Methods<\/jats:title>EORTC QLQ<\/jats:styled-content>\u2010C30 was administered at screening, on day 1 of each cycle, at the end\u2010of\u2010treatment visit, and every 8\u00a0wk until progression. EORTC QLQ<\/jats:styled-content>\u2010C30 scores were evaluated among patients with a valid baseline and at least one post\u2010baseline HRQ<\/jats:styled-content>oL assessment.<\/jats:p><\/jats:sec>Results<\/jats:title>At baseline, domain scores were similar between arms. By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP<\/jats:styled-content>. From cycle 5 onwards, improvements relative to baseline\/MP<\/jats:styled-content> were observed for all domains with VMP<\/jats:styled-content>. Mean scores were generally improved by the end\u2010of\u2010treatment assessment vs. baseline in both arms. Among responding patients, mean scores generally improved from time of response to end\u2010of\u2010treatment assessment, substantially driven by patients achieving complete response (CR<\/jats:styled-content>). Multivariate analysis showed a significant impact of duration of response\/CR<\/jats:styled-content> on improving global health status, pain, and appetite loss scores. Analyses by bortezomib dose intensity indicated better HRQ<\/jats:styled-content>oL in patients receiving lower dose intensity.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>These findings demonstrate clinically meaningful, transitory HRQ<\/jats:styled-content>oL decrements with VMP<\/jats:styled-content> and relatively lower HRQ<\/jats:styled-content>oL vs. MP<\/jats:styled-content> during early treatment cycles, associated with the expected additional toxicities. However, HRQ<\/jats:styled-content>oL is not compromised in the long term, recovering by the end\u2010of\u2010treatment visit to be comparable vs. MP<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1600-0609.2012.01788.x","type":"journal-article","created":{"date-parts":[[2012,4,3]],"date-time":"2012-04-03T19:09:01Z","timestamp":1333480141000},"page":"16-27","source":"Crossref","is-referenced-by-count":59,"title":["Health\u2010related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP<\/scp> vs. MP<\/scp>: results from the VISTA<\/scp> trial"],"prefix":"10.1111","volume":"89","author":[{"given":"Michel","family":"Delforge","sequence":"first","affiliation":[{"name":"University Hospital Leuven Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravinder","family":"Dhawan","sequence":"additional","affiliation":[{"name":"Janssen Global Services Raritan NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Don","family":"Robinson","sequence":"additional","affiliation":[{"name":"Janssen Global Services Raritan NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Meunier","sequence":"additional","affiliation":[{"name":"MAPI Consultancy Lyon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Regnault","sequence":"additional","affiliation":[{"name":"MAPI Consultancy Lyon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dixie\u2010Lee","family":"Esseltine","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals Inc Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Cakana","sequence":"additional","affiliation":[{"name":"Oncology R&D, Janssen Research & Development High Wycombe UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helgi","family":"van de Velde","sequence":"additional","affiliation":[{"name":"Oncology R&D, Janssen Research & Development Beerse Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas F.","family":"San Miguel","sequence":"additional","affiliation":[{"name":"Hospital Universitario Salamanca CIC, IBMCC (USAL\u2010CSIC) Salamanca Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,5,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7599.2006.00122.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0902-4441.2003.00195.x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704465"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.352889.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.3439"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.10.006"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.222667.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-104984"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13782"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.402"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01524.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61537-2"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.0948"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.313"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0638"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68338-4"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149427"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8216"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237974"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.1610"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-307645"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01303.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1385\/MO:18:1:65"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00346.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00509.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1224-1"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.0824"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07378.x"},{"key":"e_1_2_9_33_1","unstructured":"National Cancer Institute.National cancer institute cancer therapy evaluation program common terminology criteria for adverse events version 3.0http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00448-8"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-79"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01404.x"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66461-6"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.025"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.2080"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.2668"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01533.x"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275800"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70187-X"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294983"},{"key":"e_1_2_9_47_1","first-page":"812","article-title":"Patient\u2010reported quality of life (QoL) in elderly, newly diagnosed multiple myeloma (MM) patients receiving bortezomib\u2010based combinations: results from all randomized patients in the community\u2010based, phase 3b UPFRONT study","volume":"118","author":"Niesvizky R","year":"2011","journal-title":"Blood"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1060"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-201053"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11534"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2012.01788.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2012.01788.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T08:23:04Z","timestamp":1698740584000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2012.01788.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,7]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1111\/j.1600-0609.2012.01788.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01788.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,7]]}}}